Streetbeat News

Analyst Ratings

SAGE

Sage Therapeutics' stock is experiencing a decline following a downgrade by RBC Capital from Sector Perform to Underperform, with a price target reduction from $10 to $4.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:14 pm

HUM

UBS analyst Kevin Caliendo maintains a Neutral rating on Humana (NYSE:HUM) and lowers the price target from $380 to $250.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:13 pm

EVGO

EVgo shares rise as TD Cowen upgrades the stock from Hold to Buy, increasing the price target from $5 to $7.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:12 pm

MKTX

Citigroup analyst Christopher Allen has maintained a Buy rating on MarketAxess Holdings and raised the price target from $310 to $325.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:10 pm

PWR

Citigroup analyst Andrew Kaplowitz has maintained a Buy rating on Quanta Services and raised the price target from $302 to $348.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:09 pm

IRTC

iRhythm Technologies shares declined after Goldman Sachs initiated coverage with a Neutral rating and set a price target of $78.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:07 pm

ZS

Citigroup analyst Fatima Boolani maintains a Buy rating on Zscaler but lowers the price target from $240 to $230.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:05 pm

ANF

Abercrombie & Fitch shares rise as JP Morgan maintains an Overweight rating and slightly increases the price target from $194 to $195. The stock also benefits from positive sentiment following a tentative agreement in the dockworker strike.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:04 pm

WING

Citigroup analyst Jon Tower maintains a Neutral rating on Wingstop (NASDAQ:WING) but raises the price target from $417 to $440.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 7:03 pm

RGLD

In the past three months, six analysts have provided ratings for Royal Gold (NASDAQ:RGLD), with a mix of somewhat bullish and indifferent sentiments. The average 12-month price target has increased by 5.11% to $161.17. Analysts have raised their price targets, reflecting a positive outlook on Royal Gold's financial performance, including strong revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 7:02 pm